Incivek is used for people with genotype 1 chronic hepatitis C with compensated liver disease including cirrhosis.
The drug has been approved by Health Canada for use in combination with pegylated-interferon and ribavirin, which also help in the treatment of hepatitis C.
The Canadian approval of the drug candidate occurred following a global Phase 3 clinical trial that yielded positive results.
The trial which comprised over 2,500 people with hepatitis C demonstrated higher rates of viral cure in patients who received Incivek combination treatment as compared to those who received pegylated-interferon and ribavirin alone.